基于免疫相关基因构建口腔鳞癌临床预后模型

doi:10.13591/j.cnki.kqyx.2022.10.002

摘要/Abstract

摘要： 目的筛选口腔鳞状细胞癌(oral squamous cell carcinoma,OSCC)中关键的免疫相关基因(immune-related genes,IRGs),并构建免疫相关预后模型来预测OSCC患者的总生存期,为口腔鳞癌临床治疗方案的制定提供依据。方法首先从癌症基因组图谱(The Cancer Genome Atlas,TCGA)数据库中下载OSCC基因表达数据和相应临床信息。随后确定差异表达的IRGs,通过单因素Cox回归分析、Lasso-Cox回归分析以及多因素Cox回归分析建立免疫相关预后模型,并验证预后模型的预测性能。结果本研究构建了由6个IRGs组成的预后模型。低风险组和高风险组的总生存率差异显著(P<0.05)。1、3、5年受试者工作特征(receiver operating characteristic,ROC)曲线的曲线下面积(area under the curve,AUC)分别为0.72、0.73、0.76,这表明预后模型的预测效果较好。随后的单因素和多因素Cox回归分析证明该预后模型的风险评分是独立预后因素(P<0.001)。结论本研究确定了以6个IRGs为基础的预后模型,从而准确预测OSCC患者的预后。这一发现有助于临床医生对OSCC患者进行个体化治疗,进而提高患者生存率。

关键词: 免疫相关基因, 预后模型, 列线图, 口腔鳞状细胞癌

Abstract: Objective To screen key immune-related genes (IRGs) in oral squamous cell carcinoma (OSSC) and construct an immune-related prognostic model to predict the overall survival of patients with OSCC, so as to provide a basis for the planning of clinical treatment of oral squamous cell carcinoma. Methods Firstly, the OSCC gene expression data and corresponding clinical information were downloaded from The Cancer Genome Atlas (TCGA) database. Then the differentially expressed IRGs was determined. The immune-related prognostic model was established by univariate Cox regression analysis, Lasso-Cox regression analysis and multivariate Cox regression analysis, and the predictive performance of the model was verified. Results In this study, a prognostic model consisting of 6 IRGs was constructed. There was significant difference in total survival rate between low risk group and high risk group (P<0.05). The area under the curve (AUC) of the 1-, 3- and 5-year receiver operating characteristic(ROC) curves were 0.72, 0.73, 0.76 respectively, which indicated that the prognostic model had a good predictive effect. Subsequent univariate and multivariate Cox regression analysis showed that the risk score of the prognostic model was an independent prognostic factor (P<0.001). Conclusion In this study, 6 IRGs-based prognostic model is established to accurately predict the prognosis of patients with OSCC. This finding is helpful for clinicians to individualize treatment of patients with OSCC, and then improve the survival rate of these patients.

Key words: immune-related gene, prognostic model, nomogram, oral squamous cell carcinoma

中图分类号:

R739.85

张竞飞, 李玲, 秦汉, 王智, 李云玲, 刘敬华, 蔡圳. 基于免疫相关基因构建口腔鳞癌临床预后模型[J]. 口腔医学, 2022, 42(10): 869-877.

ZHANG Jingfei, LI Ling, QIN Han, WANG Zhi, LI Yunling, LIU Jinghua, CAI Zhen. Construction of clinical prognostic model of oral squamous cell carcinoma based on immune-related genes[J]. Stomatology, 2022, 42(10): 869-877.

参考文献

[1] Eckert AW, Kappler M, Große I, et al. Current understanding of the HIF-1-dependent metabolism in oral squamous cell carcinoma[J]. Int J Mol Sci, 2020, 21(17):6083.
[2] Lu YH, Zheng ZC, Yuan YY, et al. The emerging role of exosomes in oral squamous cell carcinoma[J]. Front Cell Dev Biol, 2021, 9:628103.
[3] Bugshan A, Farooq I. Oral squamous cell carcinoma:Metastasis, potentially associated malignant disorders, etiology and recent advancements in diagnosis[J]. F1000 Research, 2020, 9:229.
[4] Sasahira T, Kirita T. Hallmarks of cancer-related newly prognostic factors of oral squamous cell carcinoma[J]. Int J Mol Sci, 2018, 19(8):2413.
[5] Russo D,Mariani P, Caponio VCA, et al. Development and validation of prognostic models for oral squamous cell carcinoma:A systematic review and appraisal of the literature[J]. Cancers, 2021, 13(22):5755.
[6] Wang Z, Zhu J, Liu YJ, et al. Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma[J]. J Transl Med, 2020, 18(1):67.
[7] Liu B, Fu TT, He P, et al. Construction of a five-gene prognostic model based on immune-related genes for the prediction of survival in pancreatic cancer[J]. Biosci Rep, 2021, 41(7):BSR20204301.
[8] Martinez-Bosch N,Vinaixa J, Navarro P. Immune evasion in pancreatic cancer:From mechanisms to therapy[J]. Cancers, 2018, 10(1):6.
[9] Gromisch C, Qadan M, Machado MA, et al. Pancreatic adenocarcinoma:Unconventional approaches for an unconventional disease[J]. Cancer Res, 2020, 80(16):3179-3192.
[10] Pang X, Wang SS, Zhang M, et al. OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway[J]. Cancer Immunol Immunother, 2021, 70(4):1015-1029.
[11] Parikh A, Shin J, Faquin W, et al. Malignant cell-specific CXCL14 promotes tumor lymphocyte infiltration in oral cavity squamous cell carcinoma[J]. J Immunother Cancer, 2020, 8(2):e001048.
[12] Cai JH, Qiao B, Gao N, et al. Oral squamous cell carcinoma-derived exosomes promote M2 subtype macrophage polarization mediated by exosome-enclosed miR-29a-3p[J]. Am J Physiol Cell Physiol, 2019, 316(5):C731-C740.
[13] Yang ZC, Yan GX, Zheng LX, et al. YKT6, as a potential predictor of prognosis and immunotherapy response for oral squamous cell carcinoma, is related to cell invasion, metastasis, and CD8⁺ T cell infiltration[J]. Oncoimmunology, 2021, 10(1):1938890.
[14] Hui D, Maxwell JP, Paiva CE. Dealing with prognostic uncertainty:The role of prognostic models and websites for patients with advanced cancer[J]. Curr Opin Support Palliat Care, 2019, 13(4):360-368.
[15] Chen Y, Li ZY, Zhou GQ, et al. An immune-related gene prognostic index for head and neck squamous cell carcinoma[J]. Clin Cancer Res, 2021, 27(1):330-341.
[16] Cho SH, Pak K, Jeong DC, et al. The AP2M1 gene expression is a promising biomarker for predicting survival of patients with hepatocellular carcinoma[J]. J Cell Biochem, 2019, 120(3):4140-4146.
[17] Zhou F, Chen AX, Lv HY, et al. Establishment of an immune-related gene prognostic model for head and neck tumors[J]. J Biol Regul Homeost Agents, 2021, 35(3):975-986.
[18] Tang JF, Fang XD, Chen J, et al. Long non-coding RNA (lncRNA) in oral squamous cell carcinoma:Biological function and clinical application[J]. Cancers, 2021, 13(23):5944.
[19] Chaudhary A, Bag S, Arora N, et al. Hypoxic transformation of immune cell metabolism within the microenvironment of oral cancers[J]. Front Oral Health, 2020, 1:585710.
[20] Locy H, de Mey S, de Mey W, et al. Immunomodulation of the tumor microenvironment:Turn foe into friend[J]. Front Immunol, 2018, 9:2909.
[21] Kujan O, van Schaijik B, Farah CS. Immune checkpoint inhibitors in oral cavity squamous cell carcinoma and oral potentially malignant disorders:A systematic review[J]. Cancers, 2020, 12(7):1937.
[22] Kujan O, Agag M, Smaga M, et al. PD-1/PD-L1, Treg-related proteins, and tumour-infiltrating lymphocytes are associated with the development of oral squamous cell carcinoma[J]. Pathology, 2022, 54(4):409-416.
[23] Lenouvel D, González-Moles MÁ, Ruiz-Ávila I, et al. Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma:A systematic review and comprehensive meta-analysis[J]. Oral Oncol, 2020, 106:104722.
[24] Gao AT, Pan X, Yang XD, et al. Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors[J]. Invest New Drugs, 2021, 39(4):1132-1138.
[25] Hou C, Cai HS, Zhu Y, et al. Development and validation of autophagy-related gene signature and nomogram for predicting survival in oral squamous cell carcinoma[J]. Front Oncol, 2020, 10:558596.
[26] Li HY, Zhang XL, Yi C, et al. Ferroptosis-related gene signature predicts the prognosis in oral squamous cell carcinoma patients[J]. BMC Cancer, 2021, 21(1):835.
[27] Zhang YY, Mao MH, Han ZX. Identification of a gene prognostic signature for oral squamous cell carcinoma by RNA sequencing and bioinformatics[J]. Biomed Res Int, 2021, 2021:6657767.
[28] Meng L, Zhao YQ, Bu WH, et al. Bone mesenchymal stem cells are recruited via CXCL8-CXCR2 and promote EMT through TGF-β signal pathways in oral squamous carcinoma[J]. Cell Prolif, 2020, 53(8):e12859.
[29] Li SM, Mai ZY, Gu WL, et al. Molecular subtypes of oral squamous cell carcinoma based on immunosuppression genes using a deep learning approach[J]. Front Cell Dev Biol, 2021, 9:687245.
[30] Li YS, Jia SH, Dai W. Fisetin modulates human oral squamous cell carcinoma proliferation by blocking PAK4 signaling pathways[J]. Drug Des Devel Ther, 2020, 14:773-782.
[31] Huang GZ, Wu QQ, Zheng ZN, et al. Bioinformatics analyses indicate that cathepsin G (CTSG) is a potential immune-related biomarker in oral squamous cell carcinoma (OSCC)[J]. Onco Targets Ther, 2021, 14:1275-1289.
[32] Hang JJ, Lau SYF, Yin RH, et al. The role of phosphoprotein phosphatases catalytic subunit genes in pancreatic cancer[J]. Biosci Rep, 2021, 41(1):BSR20203282.
[33] Xie WJ, Sun Y, Zeng Y, et al. Comprehensive analysis of PPPCs family reveals the clinical significance of PPP1CA and PPP4C in breast cancer[J]. Bioengineered, 2022, 13(1):190-205.
[34] Zhang XX, Ni B, Li Q, et al. GPAA1 promotes gastric cancer progression via upregulation of GPI-anchored protein and enhancement of ERBB signalling pathway[J]. J Exp Clin Cancer Res, 2019, 38(1):214.
[35] Kato T, Takeda Y, Ito H, et al. GPI-80 as a useful index for myeloid cell heterogeneity and a potential prognostic biomarker for metastatic renal cell carcinoma[J]. Tohoku J Exp Med, 2019, 249(3):203-212.
[36] Li YX, Liu HR. Clinical powers of aminoacyl tRNA synthetase complex interacting multifunctional protein 1 (AIMP1) for head-neck squamous cell carcinoma[J]. Cancer Biomark, 2022, 34(3):359-374.
[37] Gao W, An CM, Xue XT, et al. Mass spectrometric analysis identifies AIMP1 and LTA4H as FSCN₁-binding proteins in laryngeal squamous cell carcinoma[J]. Proteomics, 2019, 19(21/22):e1900059.